Swiss drug manufacturer Roche announced Monday it has signed an exclusive partnership and licensing deal with Nurix Therapeutics valued at up to $2.3 billion.
The agreement centers on developing bexobrutideg, a blood cancer treatment that works by breaking down specific proteins. The medication is scheduled to begin phase III clinical testing for chronic lymphocytic leukaemia (CLL) during the summer months.
Under the terms, Nurix Therapeutics will collect $700 million in immediate payments, along with potential additional compensation tied to development progress, regulatory approvals and sales achievements.
“We believe bexobrutideg could represent a major leap forward in the fight against complex blood cancers and other diseases,” stated Levi Garraway, Roche chief medical officer and head of global product development.
The partnership is scheduled to finalize during the third quarter of 2026.
Roche will shoulder 60% of the drug’s development expenses, while Nurix will handle the remaining 40%.
Both companies plan to jointly market the treatment within the United States, sharing profits and losses equally. For international markets outside the U.S., Roche will handle commercialization independently while paying royalties to Nurix.
